Logo image
Photoreceptor layer topography in children with leber congenital amaurosis caused by RPE65 mutations
Journal article   Open access   Peer reviewed

Photoreceptor layer topography in children with leber congenital amaurosis caused by RPE65 mutations

Samuel G Jacobson, Artur V Cideciyan, Tomas S Aleman, Alexander Sumaroka, Elizabeth A M Windsor, Sharon B Schwartz, Elise Heon and Edwin M Stone
Investigative ophthalmology & visual science, Vol.49(10), pp.4573-4577
10/2008
DOI: 10.1167/iovs.08-2121
PMCID: PMC2731624
PMID: 18539930
url
https://www.ncbi.nlm.nih.gov/pmc/articles/2731624View
Open Access

Abstract

To study the topography of photoreceptor loss early in the course of Leber congenital amaurosis (LCA) caused by RPE65 mutations. Young patients with RPE65-LCA (n = 9; ages, 6-17 years) were studied with optical coherence tomography (OCT) in a wide region of central retina. Outer nuclear layer (ONL) thickness was mapped topographically and compared with that in normal subjects and in older patients with RPE65-LCA. Photoreceptor layer topography was abnormal in all young patients with RPE65-LCA. Foveal and extrafoveal ONL was reduced in most patients. There were interindividual differences, with ONL thicknesses at most retinal locations ranging from near the detectability limit to a significant fraction of normal. These differences were not clearly related to age. In most patients, there was a thinner ONL inferior to the fovea compared with that in the superior retina. Summary maps obtained by aligning and averaging photoreceptor topography across all young patients showed a relative preservation of ONL in the superior-temporal and temporal pericentral retina. These retinal regions also showed the greatest magnitude of interindividual variation. Photoreceptor loss in the foveal and extrafoveal retina was prominent, even in the youngest patients studied. Differences in the topography of residual photoreceptors in children with RPE65-LCA suggest that it may be advisable to use individualized ONL mapping to guide the location of subretinal injections for gene therapy and thereby maximize the potential for efficacy.
Genetic Therapy Retinal Degeneration - diagnosis Retinal Degeneration - genetics Tomography, Optical Coherence Blindness - diagnosis Humans Blindness - genetics Retinal Ganglion Cells - pathology Carrier Proteins - genetics Retinal Degeneration - therapy Adolescent Adult Blindness - therapy Eye Proteins - genetics Mutation Child Photoreceptor Cells, Vertebrate - pathology cis-trans-Isomerases

Details

Metrics

Logo image